{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T22:25:13Z","timestamp":1789597513724,"version":"build-2803163510"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006260","name":"Rheumatology Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006260","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007820","name":"Alliance for Lupus Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007820","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.coi.2019.09.004","type":"journal-article","created":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T22:05:41Z","timestamp":1573682741000},"page":"92-99","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":127,"special_numbering":"C","title":["B cell targeted therapies in autoimmune disease"],"prefix":"10.1016","volume":"61","author":[{"given":"Jennifer L","family":"Barnas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard John","family":"Looney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer H","family":"Anolik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2019.09.004_bib0005","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nrrheum.2012.58","article-title":"Follicular helper T cells in immunity and systemic autoimmunity","volume":"8","author":"Craft","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.coi.2019.09.004_bib0010","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.3389\/fimmu.2017.01986","article-title":"Bruton's tyrosine kinase, a component of B cell signaling pathways, has multiple roles in the pathogenesis of lupus","volume":"8","author":"Satterthwaite","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2019.09.004_bib0015","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13075-017-1500-0","article-title":"Highly selective inhibition of Bruton\u2019s tyrosine kinase attenuates skin and brain disease in murine lupus","volume":"20","author":"Chalmers","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.coi.2019.09.004_sbref0020","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nrneph.2016.20","article-title":"Plasma cells as an innovative target in autoimmune disease with renal manifestations","volume":"12","author":"Hiepe","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.coi.2019.09.004_bib0025","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/rheumatology\/kex067","article-title":"Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples","volume":"56","author":"Reddy","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.coi.2019.09.004_bib0030","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.msard.2018.12.040","article-title":"Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis","volume":"29","author":"McCool","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.coi.2019.09.004_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","author":"Cree","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2019.09.004_sbref0040","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2018-214539","article-title":"Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients","author":"Humby","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2019.09.004_bib0045","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3389\/fmed.2019.00046","article-title":"Synovial tissue: turning the page to precision medicine in arthritis","volume":"6","author":"Triaille","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.coi.2019.09.004_bib0050","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1136\/ard.2007.074229","article-title":"Assessment of rituximab\u2019s immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results","volume":"67","author":"Kavanaugh","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2019.09.004_bib0055","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1136\/ard.2007.080960","article-title":"Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response","volume":"67","author":"Thurlings","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2019.09.004_sbref0060","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.2215\/CJN.01070118","article-title":"Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis","volume":"13","author":"Gomez Mendez","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.coi.2019.09.004_bib0065","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12974-018-1136-2","article-title":"Human central nervous system astrocytes support survival and activation of B cells: implications for MS pathogenesis","volume":"15","author":"Touil","year":"2018","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.coi.2019.09.004_bib0070","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1136\/annrheumdis-2017-211191","article-title":"Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus","volume":"76","author":"Md Yusof","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2019.09.004_bib0075","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/s41584-018-0065-x","article-title":"B cell therapy in ANCA-associated vasculitis: current and emerging treatment options","volume":"14","author":"McClure","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.coi.2019.09.004_bib0080","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1172\/JCI85113","article-title":"Human regulatory B cells in health and disease: therapeutic potential","volume":"127","author":"Mauri","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coi.2019.09.004_bib0085","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1002\/art.22810","article-title":"Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy","volume":"56","author":"Anolik","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2019.09.004_sbref0090","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.immuni.2016.02.012","article-title":"A regulatory feedback between plasmacytoid dendritic cells and regulatory B cells is aberrant in systemic lupus erythematosus","volume":"44","author":"Menon","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.coi.2019.09.004_bib0095","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aab4176","article-title":"Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy","volume":"7","author":"Li","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coi.2019.09.004_bib0100","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1084\/jem.20111675","article-title":"B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells","volume":"209","author":"Barr","year":"2012","journal-title":"J Exp Med"},{"key":"10.1016\/j.coi.2019.09.004_bib0105","doi-asserted-by":"crossref","first-page":"9773","DOI":"10.1073\/pnas.1810470115","article-title":"Functional characterization of reappearing B cells after anti-CD20 treatment of CNS autoimmune disease","volume":"115","author":"Hausler","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coi.2019.09.004_sbref0110","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cell.2018.08.011","article-title":"Memory B cells activate brain-homing, autoreactive CD4(+) T cells in multiple sclerosis","volume":"175","author":"Jelcic","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.coi.2019.09.004_bib0115","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/art.39489","article-title":"Production of RANKL by memory B cells: a link between b cells and bone erosion in rheumatoid arthritis","volume":"68","author":"Meednu","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2019.09.004_bib0120","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1136\/annrheumdis-2013-204116","article-title":"Expression of FcRL4 defines a pro-inflammatory, RANKL-producing B cell subset in rheumatoid arthritis","volume":"74","author":"Yeo","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2019.09.004_bib0125","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13075-016-0957-6","article-title":"Generation mechanism of RANKL(+) effector memory B cells: relevance to the pathogenesis of rheumatoid arthritis","volume":"18","author":"Ota","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.coi.2019.09.004_bib0130","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jaut.2017.03.004","article-title":"B cells expressing the IgA receptor FcRL4 participate in the autoimmune response in patients with rheumatoid arthritis","volume":"81","author":"Amara","year":"2017","journal-title":"J Autoimmun"},{"key":"10.1016\/j.coi.2019.09.004_sbref0135","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.immuni.2018.08.015","article-title":"Distinct effector B cells induced by unregulated toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus","volume":"49","author":"Jenks","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.coi.2019.09.004_bib0140","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1002\/art.38637","article-title":"Citrulline-specific Th1 cells are increased in rheumatoid arthritis and their frequency is influenced by disease duration and therapy","volume":"66","author":"James","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2019.09.004_bib0145","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/eji.201445036","article-title":"B cells expressing IFN-gamma suppress Treg-cell differentiation and promote autoimmune experimental arthritis","volume":"45","author":"Olalekan","year":"2015","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.coi.2019.09.004_sbref0150","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-07626-8","article-title":"B cells inhibit bone formation in rheumatoid arthritis by suppressing osteoblast differentiation","volume":"9","author":"Sun","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.coi.2019.09.004_bib0155","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/ni.3175","article-title":"Diversity, cellular origin and autoreactivity of antibody-secreting cell population expansions in acute systemic lupus erythematosus","volume":"16","author":"Tipton","year":"2015","journal-title":"Nat Immunol"},{"key":"10.1016\/j.coi.2019.09.004_bib0160","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1182\/blood-2011-01-330530","article-title":"A B-cell subset uniquely responsive to innate stimuli accumulates in aged mice","volume":"118","author":"Hao","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.coi.2019.09.004_bib0165","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1182\/blood-2011-01-331462","article-title":"Toll-like receptor 7 (TLR7)-driven accumulation of a novel CD11c(+) B-cell population is important for the development of autoimmunity","volume":"118","author":"Rubtsov","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.coi.2019.09.004_bib0170","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.cellimm.2014.12.002","article-title":"TLR7, IFNgamma, and T-bet: their roles in the development of ABCs in female-biased autoimmunity","volume":"294","author":"Rubtsova","year":"2015","journal-title":"Cell Immunol"},{"key":"10.1016\/j.coi.2019.09.004_bib0175","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1172\/JCI91250","article-title":"B cells expressing the transcription factor T-bet drive lupus-like autoimmunity","volume":"127","author":"Rubtsova","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coi.2019.09.004_sbref0180","article-title":"IL-21 drives expansion and plasma cell differentiation of autoreactive CD11c(hi)T-bet(+) B cells in SLE","volume":"9","author":"Wang","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.coi.2019.09.004_sbref0185","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature20810","article-title":"Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis","volume":"542","author":"Rao","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.coi.2019.09.004_bib0190","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41591-018-0254-9","article-title":"A CD4(+) T cell population expanded in lupus blood provides B cell help through interleukin-10 and succinate","volume":"25","author":"Caielli","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.coi.2019.09.004_sbref0195","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.coi.2018.10.008","article-title":"The long and the short of it: insights into the cellular source of autoantibodies as revealed by B cell depletion therapy","volume":"55","author":"Hale","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.coi.2019.09.004_bib0200","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1681\/ASN.2017040367","article-title":"Targeting B cells and plasma cells in glomerular diseases: translational perspectives","volume":"29","author":"Schrezenmeier","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.coi.2019.09.004_bib0205","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1056\/NEJMoa066092","article-title":"Duration of humoral immunity to common viral and vaccine antigens","volume":"357","author":"Amanna","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2019.09.004_bib0210","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-01901-w","article-title":"Plasma cell survival in the absence of B cell memory","volume":"8","author":"Hammarlund","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.coi.2019.09.004_sbref0215","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.immuni.2015.06.016","article-title":"Long-lived plasma cells are contained within the CD19(-)CD38(hi)CD138(+) subset in human bone marrow","volume":"43","author":"Halliley","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.coi.2019.09.004_bib0220","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.4049\/jimmunol.1302003","article-title":"Long-term B cell depletion in murine lupus eliminates autoantibody-secreting cells and is associated with alterations in the kidney plasma cell niche","volume":"192","author":"Wang","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.coi.2019.09.004_bib0225","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nri1886","article-title":"Competence and competition: the challenge of becoming a long-lived plasma cell","volume":"6","author":"Radbruch","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.coi.2019.09.004_bib0230","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13075-015-0529-1","article-title":"Proteasome inhibitors as experimental therapeutics of autoimmune diseases","volume":"17","author":"Verbrugge","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.coi.2019.09.004_bib0235","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/art.33333","article-title":"Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells","volume":"64","author":"Ichikawa","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2019.09.004_bib0240","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1200\/JCO.2005.04.6474","article-title":"Flare in neuropathy following rituximab therapy for Waldenstrom\u2019s macroglobulinemia","volume":"24","author":"Noronha","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coi.2019.09.004_sbref0245","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1002\/eji.201847492","article-title":"Proteasome inhibition with bortezomib induces a therapeutically relevant depletion of plasma cells in SLE but does not target their precursors","volume":"48","author":"Alexander","year":"2018","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.coi.2019.09.004_bib0250","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2019.09.004_sbref0255","first-page":"11","article-title":"Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus","author":"Kansal","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coi.2019.09.004_bib0260","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2016-01-694356","article-title":"Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy","volume":"128","author":"Bhoj","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.coi.2019.09.004_bib0265","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00277-018-03592-9","article-title":"Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma","volume":"98","author":"Ma","year":"2019","journal-title":"Ann Hematol"},{"key":"10.1016\/j.coi.2019.09.004_bib0270","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095279151930038X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095279151930038X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T12:36:27Z","timestamp":1763642187000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095279151930038X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":54,"alternative-id":["S095279151930038X"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2019.09.004","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"B cell targeted therapies in autoimmune disease","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2019.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}